PIK3CA and lymphangioma: For example, rapamycin that targets the PI3K-AKT downstream effector mTOR has shown efficacy in relieving symptoms in VM and LM patients although it rarely results in the regression of lesions (Queisser et al., 2021; Mäkinen et al., 2021).